U.K. agency favors NHS coverage of Remicade for colitis

12/17/2008 | Reuters

The U.K.'s National Institute for Health and Clinical Excellence endorsed Schering-Plough's Remicade for National Health Service coverage as an alternative for patients with ulcerative colitis who do not respond to ciclosporin.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD